Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer.
A soluble protein fragment drives triple-negative breast cancer cell migration, opening potential new targets for treatment.
This diagnostic validation study examined Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer. The abstract reports that Functionally, recombinant EphA2-P328 promoted TNBC-cell migration and induced cell context-dependent changes in EMT-associated markers in vitro.
What the study was
- Study design
- Diagnostic validation study
- Population
- Human participants
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Transl Oncol
Why it surfaced
Diagnostic validation study; directly matches Early cancer detection. Conservative abstract-level score 8/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.